{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T09:56:16Z","timestamp":1794995776802,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science and Technology Council, Taiwan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67326-y","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:26:31Z","timestamp":1765463191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0399-3329","authenticated-orcid":false,"given":"Cheng-Hao","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-9362","authenticated-orcid":false,"given":"Glen P.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-1473","authenticated-orcid":false,"given":"Benjamin P.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6722-1153","authenticated-orcid":false,"given":"Tsai-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8684-2107","authenticated-orcid":false,"given":"Zhujun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2703-5954","authenticated-orcid":false,"given":"Yee Hui","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-1801","authenticated-orcid":false,"given":"Chun-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"67326_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"C Murray","year":"2022","unstructured":"Murray, C. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629\u2013655 (2022).","journal-title":"Lancet"},{"key":"67326_CR2","doi-asserted-by":"publisher","first-page":"e15644","DOI":"10.1111\/liv.15644","volume":"45","author":"C Engelmann","year":"2025","unstructured":"Engelmann, C., Zhang, I. W. & Claria, J. Mechanisms of immunity in acutely decompensated cirrhosis and acute-on-chronic liver failure. Liver Int. 45, e15644 (2025).","journal-title":"Liver Int."},{"key":"67326_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S2468-1253(24)00224-3","volume":"9","author":"Z Cao","year":"2024","unstructured":"Cao, Z. et al. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. Lancet Gastroenterol. Hepatol. 9, 997\u20131009 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"67326_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jhep.2020.07.046","volume":"74","author":"F Wong","year":"2021","unstructured":"Wong, F. et al. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J. Hepatol. 74, 330\u2013339 (2021).","journal-title":"J. Hepatol."},{"key":"67326_CR5","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2018.12.005","volume":"156","author":"S Piano","year":"2019","unstructured":"Piano, S. et al. Epidemiology and effects of bacterial infections in patients with cirrhosis Worldwide. Gastroenterology 156, 1368\u20131380.e1310 (2019).","journal-title":"Gastroenterology"},{"key":"67326_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2018.10.027","volume":"70","author":"J Fernandez","year":"2019","unstructured":"Fernandez, J. et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J. Hepatol. 70, 398\u2013411 (2019).","journal-title":"J. Hepatol."},{"key":"67326_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jhep.2024.02.023","volume":"80","author":"R Martin-Mateos","year":"2024","unstructured":"Martin-Mateos, R. et al. Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors. J. Hepatol. 80, 904\u2013912 (2024).","journal-title":"J. Hepatol."},{"key":"67326_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/hep.31708","volume":"74","author":"P Caraceni","year":"2021","unstructured":"Caraceni, P. et al. The use of Rifaximin in patients with cirrhosis. Hepatology 74, 1660\u20131673 (2021).","journal-title":"Hepatology"},{"key":"67326_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071\u20131081 (2010).","journal-title":"N. Engl. J. Med."},{"key":"67326_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/apt.14361","volume":"46","author":"A Goel","year":"2017","unstructured":"Goel, A., Rahim, U., Nguyen, L. H., Stave, C. & Nguyen, M. H. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharm. Ther. 46, 1029\u20131036 (2017).","journal-title":"Aliment Pharm. Ther."},{"key":"67326_CR11","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.44.11.3163-3166.2000","volume":"44","author":"A O\u2019Neill","year":"2000","unstructured":"O\u2019Neill, A. et al. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 44, 3163\u20133166 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"67326_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41564-018-0245-0","volume":"3","author":"NC Howard","year":"2018","unstructured":"Howard, N. C. et al. Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes. Nat. Microbiol. 3, 1099\u20131108 (2018).","journal-title":"Nat. Microbiol."},{"key":"67326_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/liv.15667","volume":"43","author":"LM Schulte","year":"2023","unstructured":"Schulte, L. M., Nattermann, J., Strassburg, C. P. & Lutz, P. Rifaximin may induce rifampicin resistance in coagulase-negative staphylococci. Liver Int. 43, 2039\u20132041 (2023).","journal-title":"Liver Int."},{"key":"67326_CR14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/cid\/cix918","volume":"66","author":"E Reigadas","year":"2018","unstructured":"Reigadas, E. et al. Breakthrough Clostridium difficile infection in cirrhotic patients receiving Rifaximin. Clin. Infect. Dis. 66, 1086\u20131091 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"67326_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00039-23","volume":"36","author":"HL DuPont","year":"2023","unstructured":"DuPont, H. L. The potential for development of clinically relevant microbial resistance to rifaximin-\u03b1: a narrative review. Clin. Microbiol. Rev. 36, e0003923 (2023).","journal-title":"Clin. Microbiol. Rev."},{"key":"67326_CR16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41586-024-08095-4","volume":"635","author":"AM Turner","year":"2024","unstructured":"Turner, A. M. et al. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature 635, 969\u2013977 (2024).","journal-title":"Nature"},{"key":"67326_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-022-00366-6","volume":"8","author":"D H\u00e4ussinger","year":"2022","unstructured":"H\u00e4ussinger, D. et al. Hepatic encephalopathy. Nat. Rev. Dis. Prim. 8, 43 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"67326_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ijantimicag.2013.12.008","volume":"43","author":"A Pistiki","year":"2014","unstructured":"Pistiki, A. et al. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int. J. Antimicrob. Agents 43, 236\u2013241 (2014).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"67326_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","volume":"76","author":"VC Patel","year":"2022","unstructured":"Patel, V. C. et al. Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J. Hepatol. 76, 332\u2013342 (2022).","journal-title":"J. Hepatol."},{"key":"67326_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","volume":"72","author":"JS Bajaj","year":"2020","unstructured":"Bajaj, J. S. & Khoruts, A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. J. Hepatol. 72, 1003\u20131027 (2020).","journal-title":"J. Hepatol."},{"key":"67326_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2392880","volume":"16","author":"JS Bajaj","year":"2024","unstructured":"Bajaj, J. S. et al. Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis. Gut Microbes 16, 2392880 (2024).","journal-title":"Gut Microbes"},{"key":"67326_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41591-024-03405-9","volume":"31","author":"X He","year":"2025","unstructured":"He, X. et al. The gut-brain axis underlying hepatic encephalopathy in liver cirrhosis. Nat. Med. 31, 627\u2013638 (2025).","journal-title":"Nat. Med."},{"key":"67326_CR23","doi-asserted-by":"crossref","unstructured":"Gu\u00e9rillot, R. et al. Convergent evolution driven by rifampin exacerbates the global burden of drug-resistant Staphylococcus aureus. mSphere 3, 10\u20131128 (2018).","DOI":"10.1128\/mSphere.00550-17"},{"key":"67326_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.gastro.2021.04.013","volume":"161","author":"A Shamsaddini","year":"2021","unstructured":"Shamsaddini, A. et al. Impact of antibiotic resistance genes in gut microbiome of patients with cirrhosis. Gastroenterology 161, 508\u2013521.e507 (2021).","journal-title":"Gastroenterology"},{"key":"67326_CR25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jhep.2021.12.042","volume":"76","author":"V Prado","year":"2022","unstructured":"Prado, V. et al. Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis. J. Hepatol. 76, 1079\u20131089 (2022).","journal-title":"J. Hepatol."},{"key":"67326_CR26","doi-asserted-by":"crossref","unstructured":"Lee, S. et al. Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance. J. Hepatol. 82, 622\u2013633 (2024).","DOI":"10.1016\/j.jhep.2024.09.046"},{"key":"67326_CR27","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41564-024-01680-3","volume":"9","author":"C Liao","year":"2024","unstructured":"Liao, C. et al. Oral bacteria relative abundance in faeces increases due to gut microbiota depletion and is linked with patient outcomes. Nat. Microbiol. 9, 1555\u20131565 (2024).","journal-title":"Nat. Microbiol."},{"key":"67326_CR28","doi-asserted-by":"crossref","unstructured":"Zacharias, H. D. et al. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst. Rev. 7, Cd011585 (2023).","DOI":"10.1002\/14651858.CD011585.pub2"},{"key":"67326_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/antibiotics14030287","volume":"14","author":"Z Bai","year":"2025","unstructured":"Bai, Z. et al. Role of Rifaximin in the prognosis of critically Ill patients with liver cirrhosis. Antibiotics 14, 287 (2025).","journal-title":"Antibiotics"},{"key":"67326_CR30","doi-asserted-by":"crossref","unstructured":"Pose, E. et al. Simvastatin and Rifaximin in decompensated cirrhosis: a randomized clinical trial. Jama 333, 864\u2013874 (2025).","DOI":"10.1001\/jama.2024.27441"},{"key":"67326_CR31","doi-asserted-by":"crossref","unstructured":"Silvey, S., Patel, N., Khoruts, A. & Bajaj, J. S. Rifaximin does not increase the rate of 30-day mortality in patients with cirrhosis and daptomycin in two National US-based cohorts. Gastroenterology 169, 349\u2013351.e3 (2025).","DOI":"10.1053\/j.gastro.2025.03.014"},{"key":"67326_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab659","volume":"9","author":"RA Lee","year":"2022","unstructured":"Lee, R. A. et al. Daptomycin-resistant enterococcus bacteremia is associated with prior daptomycin use and increased mortality after liver transplantation. Open Forum Infect. Dis. 9, ofab659 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"67326_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/jgh.12070","volume":"28","author":"J Vlachogiannakos","year":"2013","unstructured":"Vlachogiannakos, J. et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J. Gastroenterol. Hepatol. 28, 450\u2013455 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"67326_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/apt.15326","volume":"50","author":"S Salehi","year":"2019","unstructured":"Salehi, S. et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharm. Ther. 50, 435\u2013441 (2019).","journal-title":"Aliment Pharm. Ther."},{"key":"67326_CR35","doi-asserted-by":"publisher","first-page":"175628481985825","DOI":"10.1177\/1756284819858256","volume":"12","author":"RC Oey","year":"2019","unstructured":"Oey, R. C., Buck, L. E. M., Erler, N. S., van Buuren, H. R. & de Man, R. A. The efficacy and safety of rifaximin-\u03b1: a 2-year observational study of overt hepatic encephalopathy. Ther. Adv. Gastroenterol. 12, 1756284819858256 (2019).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"67326_CR36","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","volume":"12","author":"KD Mullen","year":"2014","unstructured":"Mullen, K. D. et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin. Gastroenterol. Hepatol. 12, 1390\u20131397.e1392 (2014).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"67326_CR37","doi-asserted-by":"crossref","unstructured":"Bajaj, J. S. et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial. J. Hepatol. 83, 81\u201391 (2025).","DOI":"10.1016\/j.jhep.2024.12.047"},{"key":"67326_CR38","doi-asserted-by":"crossref","unstructured":"Bloom, P. P. et al. Safety and efficacy of a defined bacterial consortium, VE303, to treat HE. Hepatol. Commun. 9, e0650 (2025).","DOI":"10.1097\/HC9.0000000000000650"},{"key":"67326_CR39","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/gutjnl-2023-330699","volume":"73","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis. Gut 73, 1183\u20131198 (2024).","journal-title":"Gut"},{"key":"67326_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.14309\/ajg.0000000000002189","volume":"118","author":"A Adejumo","year":"2023","unstructured":"Adejumo, A. et al. Dementia frequently coexists with hepatic encephalopathy but not other cirrhosis complications in US Veterans. Am. J. Gastroenterol. 118, 475\u2013480 (2023).","journal-title":"Am. J. Gastroenterol."},{"key":"67326_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00403-024-02860-1","volume":"316","author":"S Patel","year":"2024","unstructured":"Patel, S. et al. Evaluating the inpatient burden of antimicrobial resistance in hidradenitis suppurativa hospitalizations: a cross-sectional analysis. Arch. Dermatol. Res. 316, 131 (2024).","journal-title":"Arch. Dermatol. Res."},{"key":"67326_CR42","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1017\/ice.2017.192","volume":"38","author":"JP Burnham","year":"2017","unstructured":"Burnham, J. P., Kwon, J. H., Babcock, H. M., Olsen, M. A. & Kollef, M. H. ICD-9-CM coding for multidrug resistant infection correlates poorly with microbiologically confirmed multidrug resistant infection. Infect. Control Hosp. Epidemiol. 38, 1381\u20131383 (2017).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"67326_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5455\/medarh.2013.67.329-332","volume":"67","author":"P Afshar","year":"2013","unstructured":"Afshar, P. et al. Prevalence of resistance to antibiotics according to International Classification of Diseases (ICD-10) in Boo Ali Sina Hospital of Sari, 2011-2012. Med. Arch. 67, 329\u2013332 (2013).","journal-title":"Med. Arch."},{"key":"67326_CR44","doi-asserted-by":"publisher","first-page":"e0223409","DOI":"10.1371\/journal.pone.0223409","volume":"14","author":"HQ Nguyen","year":"2019","unstructured":"Nguyen, H. Q., Nguyen, N. T. Q., Hughes, C. M. & O\u2019Neill, C. Trends and impact of antimicrobial resistance on older inpatients with urinary tract infections (UTIs): a national retrospective observational study. PLoS ONE 14, e0223409 (2019).","journal-title":"PLoS ONE"},{"key":"67326_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06287-1","volume":"21","author":"M Opatowski","year":"2021","unstructured":"Opatowski, M. et al. Antibiotic prescriptions and risk factors for antimicrobial resistance in patients hospitalized with urinary tract infection: a matched case-control study using the French health insurance database (SNDS). BMC Infect. Dis. 21, 571 (2021).","journal-title":"BMC Infect. Dis."},{"key":"67326_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00059-22","volume":"36","author":"KA Cairns","year":"2023","unstructured":"Cairns, K. A. et al. Therapeutics for vancomycin-resistant enterococcal bloodstream infections. Clin. Microbiol. Rev. 36, e0005922 (2023).","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67326-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67326-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67326-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T21:02:56Z","timestamp":1769288576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67326-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67326"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67326-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"674"}}